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Profiling embryonic stem cell differentiation by
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Matthias Trost *a
MALDI TOF mass spectrometry (MS) is widely used to characterise and biotype bacterial samples, but a
complementary method for profiling of mammalian cells is still underdeveloped. Current approaches vary
dramatically in their sample preparation methods and are not suitable for high-throughput studies. In this
work, we present a universal workflow for mammalian cell MALDI TOF MS analysis and apply it to dis-
tinguish ground-state naïve and differentiating mouse embryonic stem cells (mESCs), which can be used
as a model for drug discovery. We employed a systematic approach testing many parameters to evaluate
how efficiently and reproducibly each method extracted unique mass features from four different human
cell lines. These data enabled us to develop a unique mammalian cell MALDI TOF workflow involving a
freeze–thaw cycle, methanol fixing and a CHCA matrix to generate spectra that robustly phenotype
different cell lines and are highly reproducible in peak identification across replicate spectra. We applied our
optimised workflow to distinguish naïve and differentiating populations using multivariate analysis and
reproducibly identify unique features. We were also able to demonstrate the compatibility of our optimised
method for current automated liquid handling technologies. Consequently, our MALDI TOF MS profiling
method enables identification of unique features and robust phenotyping of mESC differentiation in under
1 hour from culture to analysis, which is significantly faster and cheaper when compared with conventional
methods such as qPCR. This method has the potential to be automated and can in the future be applied to
profile other cell types and expanded towards cellular MALDI TOF MS screening assays.
Introduction
Matrix-assisted laser desorption/ionisation time of flight mass
spectrometry (MALDI TOF MS) is a versatile technique with
many different applications ranging from protein identifi-
cation by peptide mass fingerprinting and small molecule ana-
lysis to imaging of tissues.1–3 Although conventionally con-
sidered a low-throughput technology, recent advances in MS
and liquid handling technologies and liquid handling tools
have enabled MALDI TOF MS to emerge as a powerful tool for
label-free high-throughput screening (HTS) within both the
pharmaceutical industry and academic sphere.4–6 This plat-
form has been already well established for in vitro assays to
monitor post-translational modifications such as
ubiquitylation,7,8 phosphorylation9,10 and methylation,11,12 as
the read-out is relatively simple with often just a single sub-
strate and product. Similar to MALDI, laser desorption ionis-
ation can also be combined with self-assembled monolayers
(SAMs), also known as SAMDI.13,14 Here, substrates are first
immobilised on a surface before treatment with an enzyme,
thus determining activity and kinetic parameters.
Interestingly, SAMDI has been shown to be not only compati-
ble with peptide substrates for protein specificity,15,16 but also
carbohydrates for glycosyltransferase activity.17
Whole cell analysis or cellular assays for evaluating com-
pound efficacy affecting a cellular phenotype present an inter-
esting challenge for MALDI TOF MS analysis as the system
becomes inherently more complex. A well-established appli-
cation of whole cell MALDI TOF MS is the profiling of micro-
organisms, also known as biotyping.18,19 Profiling of protein
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biomarkers specific to a bacterial taxonomy by MALDI TOF MS
was first performed by Claydon et al. and enabled reproducible
and robust identification of Gram-positive and Gram-negative
species.20 Since then, bacterial genera have been identified
through various approaches from spectral mass fingerprinting,
to more complex approaches that involve comparing peaks
identified in MALDI spectra to predictive masses from proteo-
mic and genomic data sets.21,22 This in turn enabled the gene-
ration of reference protein databases that list biomarkers
specific to different bacterial species.23 Combined with auto-
mated spectral acquisition and novel algorithms to tackle data
analysis, biotyping has become a powerful, high-throughput
tool for rapidly profiling bacterial genera in both academic
and clinical settings.24 However, inter-lab studies revealed sur-
prising discrepancies in E. coli fingerprints as experimental
variables such as sample preparation and instrument para-
meters can affect spectral quality and reproducibility.25,26
Several studies have therefore scrutinised sample preparation
methods for bacterial biotyping; looking at solvent extraction
or direct analysis, sample handling and also matrix choice
affect spectra quality with the aim of developing a standar-
dised method to enable universal identification of micro-
organisms.27–29
While bacterial biotyping has been very successful and has
become a standard tool in the clinic, profiling of mammalian
cells by MALDI TOF MS has not yet reached this level. High-
resolution MALDI-FT-ICR mass spectrometry has been used by
Sweedler et al. to characterise lipids within 30 000 individual
rodent cerebellar cells.30 This study enabled the identification
of 520 lipid features and classification of neuron-like and
astrocyte-like cells, thus allowing lipid profiles to be assigned
to particular cellular functions. Characterising the protein sig-
natures of mammalian cells by MALDI-MS is less common
when compared with lipid analysis; however it has been used
for phenotypic screening of human cancer cell lines,31,32
identification of cells within a co-culture33,34 or tissues35 and
detection of transient changes within a specific cell type, such
as immune cells.36–39 However, many of these studies list dra-
matically different experimental procedures with several being
adapted from existing biotyping protocols. The huge range of
experimental parameters could therefore be problematic for
translation of published assays to the pharmaceutical industry.
To address the variation in experimental workflows, we
have systematically tested different methods at key steps in pre-
paring mammalian cells for whole cell MALDI TOF MS ana-
lysis. We have generated a robust and sensitive sample prepa-
ration workflow by studying four commonly used human cell
lines, followed by application of our final method to a pharma-
cologically controlled biological system, where we applied our
optimised method to profile differences between naïve
ground-state mouse embryonic stem cells (mESCs) and those
undergoing differentiation. Thus, we have established a
sample preparation method that is highly reproducible, robust
and sensitive with respect to both biological and experimental
variances and would be suitable for expansion to a HTS
platform.
Materials and methods
Human cell line culture
HEK293 and U2OS cell lines were cultured in DMEM media
supplemented with 10% FBS, 1% pen/strep and 1%
L-glutamine. MCF7 and THP-1 cells were cultured in
RPMI-1640 media supplemented with the same and 50 µM
β-mercaptoethanol was added to THP-1 cells. Adherent cell
lines were lifted from 10 cm culture plates by addition of
trypsin-EDTA solution. All cell lines were incubated under a
controlled atmosphere at 5% CO2 and 37 °C. Cells were har-
vested and centrifuged at 300g for 3 minutes before resuspen-
sion in PBS and counted using a haemocytometer. Cells were
then aliquoted at a concentration 1 × 106 into 1.5 mL micro-
tubes and centrifuged at 300g, 4 °C for 10 minutes.
Mouse embryonic stem cell (mESC) culture
CGR8 mESCs were cultured in 0.1% gelatin [w/v] coated plates
in N2B27 medium (DMEM/F12-Neurobasal (1 : 1), 0.5% N2,
1% B27 (ThermoFisher Scientific), 1% L-glutamine, 100 μM
β-mercaptoethanol) containing “2i”,40 3 μM CHIR99021 (Axon
Medchem) and 1 μM PD0325901, under a controlled atmo-
sphere at 5% CO2 and 37 °C. To induce multi-lineage differen-
tiation,41 cells were plated at 4 × 104 cells per cm2 in
N2B27 medium without CHIR99021 and PD0325901 and incu-
bated for 48 h at 5% CO2 and 37 °C.
RNA extraction and qPCR
Total RNA extraction was performed by using a column-based
system (Omega) and then subjected to reverse transcription
using iScript reverse transcriptase (Bio-Rad) according to the
manufacturer’s guidelines. qPCR reactions were carried out
using SYBR® Premix Ex Taq™ II Supermix (Takara) in a
CFX384 real-time PCR system (Bio-Rad). Samples were ana-
lysed for gene expression under 2i release conditions relative
to 2i medium culture using the ΔΔCt method, and GAPDH
expression was analysed as a loading control. Data from three
independent biological replicates, with two technical replicates
for each, were analysed using Excel software (Microsoft) and
plotted using GraphPad Prism v.6.00 software (GraphPad).
Primers used are listed in Table S-1.† Statistical significance
was determined using an unpaired Student’s t test, and signifi-
cant differences were considered when p < 0.05.
Cell microscopy and diameter analysis
The four cell lines were measured for number and cell dia-
meter by light microscopy using an Evos XL Core Cell Imaging
System (Invitrogen). Optimal cell numbers were calculated by a
cell titration, whose values are reported in Table S-2,† and
these concentrations were used for subsequent experiments.
To assess permeability, cell pellets were resuspended in PBS
before mixing 1 : 1 with trypan blue. Trypan blue positive cells
were then automatically counted using the same microscope
to calculate cell viability. For mESC phenotype visualisation,
brightfield light microscopy was used in a Leica DM IL LED
microscope at 10× magnification.
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BCA protein quantitation
Cells were titrated from 300 000 to 9000 in a 96 well plate
format. BCA reagent (Pierce) was then prepared according to
the manufacturer’s instruction by mixing Reagent A and
Reagent B at a ratio of 50 : 1 respectively. 20 µL of the mixed
reagent was added to 180 µL of the sample and incubated at
37 °C for 30 minutes. The plate was then read on a plate
reader measuring absorbance at 562 nm and the protein con-
centration was calculated from these values.
Sample preparation for MALDI TOF MS analysis
Cell pellets were processed in one of three ways:
(a) Direct analysis where cell pellets were washed twice with
PBS and centrifuged at 300g, 4 °C for 10 minutes. Cell pellets
were then resuspended in 0.1% TFA before subsequent
spotting.
(b) Cell pellets were snap frozen on dry ice and stored at
−80 °C until required. Thawed cell pellets were centrifuged at
300g, 4 °C for 10 minutes before either being washed 1× with
PBS or fixed in 4% paraformaldehyde solution or methanol on
ice. Cell suspensions were then centrifuged at 300g, 4 °C for
10 minutes before being resuspended in 0.1% TFA.
(c) Cell pellets were washed twice with PBS and centrifuged
at 300g, 4 °C for 10 minutes. Cell pellets were then either
washed 1× with PBS or fixed in 4% paraformaldehyde solution
or methanol on ice. Cell suspensions were then centrifuged at
300g, 4 °C for 10 minutes before being resuspended in 0.1%
snap frozen on dry ice and stored at −80 °C until required.
Matrix preparation and spotting
Sinapinic acid (SA), α-cyano-4-hydroxycinnamic acid (CHCA)
and 2,5-dihydroxybenzoic acid (DHB) were used as matrices
for all MALDI TOF cellular analysis. All matrix solutions were
prepared in 50% ACN, 0.1% TFA at varying concentrations and
ratios of matrix solute: 2.5, 10, 20 mg mL−1 or saturated. For
manual deposition, cell suspensions were mixed at a 1 : 1 ratio
with matrix solution and 1 µL was spotted onto a ground steel
MALDI target before ambient drying.
Automated target spotting was performed using a Mosquito
liquid handling robot (TTP Labtech) by first mixing 1200 nL of
matrix solution with 1200 nL of whole cell samples before sub-
sequent deposition of 200 nL of the sample:matrix mixture on
an AnchorChip MALDI. The target was allowed to ambient dry
before analysis.
MALDI TOF MS analysis
A RapifleX PharmaPulse MALDI TOF/TOF mass spectrometer
(Bruker Daltonics) equipped with a Smartbeam 3D laser was
used in positive ion mode with Compass 2.0 control for all
data acquisition. Samples were acquired in automatic mode
(AutoXecute; Bruker Daltonics), totalling 10 000 shots at a 10
kHz frequency per spot. Full MALDI TOF MS parameters can
be found in supplementary methods. MALDI TOF data were
processed using the FlexAnalysis 4.0 software where a peak
picking threshold of 3 S/N was set before being exported as a
.csv file using the FlexAnalysis Batch Process (Compass 2.0)
and further processed with Microsoft Excel and/or Perseus.42
Spectra based principal component analysis (PCA) plots were
generated using ClinPro Tools (Bruker Daltonics). Data were
then formatted using both GraphPad Prism 7.0 and Adobe
Illustrator.
Bootstrap statistical analysis
Hierarchical cluster analysis was performed on all biological
and technical replicates of the two conditions using the R
package pvclust, with multiscale bootstrap resampling of
10 000 iterations used to assess statistical significance by
approximately unbiased p-values.43,44 Clustering was
implemented using the average agglomeration method with a
correlation distance metric. The results are presented along-
side a z-score heatmap of detected mass features.45
Results and discussion
Optimising the workflow for mammalian cell MALDI TOF MS
In order to optimise the sample preparation for whole cell
MALDI TOF MS, we focused initially on four different human
cell lines (U2OS, MCF7, THP1 and HEK293) (Fig. 1A). Cells
were washed once with PBS, which was sufficient to remove
the culture medium contaminants as high levels of foetal
bovine serum (FBS) and salts from the culture medium affect
MALDI TOF MS ionisation.36 To determine the optimal cell
concentration, we spotted 25 to 20 000 cells on the target.
Surprisingly, there was a narrow window where good spectra
could be acquired, with large numbers of cells on-target
proving to be detrimental to ionisation.
Further to this, we observed that the best spectral inten-
sity varied for each cell line (Fig. 1B) and hypothesised that
the number of ionisable biomolecules from cells was depen-
dent on the cell size. This relationship was also consistent
between the protein concentration and cell number
(Fig. S1†). Therefore, we measured the diameters of all four
cell lines in solution (Table S-2†) and plotted these values
against the optimal cell number derived from the titration
to identify an optimal cell number on-target for MALDI TOF
MS analysis (Fig. 1C). This generated a linear relationship
with a very good correlation of R2 = 0.99 indicating that to
obtain optimal and reproducible spectra from mammalian
cells by MALDI TOF MS, cell numbers on the target need to
be optimised and this number is dependent on the cell
size.
We tested next if the biomolecules detected from mam-
malian cells derive from intact cells or if mild breakage of
cells enhanced the occurrence of unique mass features. In
our experience, harsh lysing conditions resulted in spectra
that were less distinguishable, which has also been observed
by lysing with increasing acidity.37 It was indicated before
that freeze–thawing of cell pellets prior to MALDI TOF MS
analysis may have beneficial effects with respect to the
number of features identified and overall spectral
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intensity.33,46 This is likely due to the freeze/thaw cycle per-
meating the cell membrane, thus allowing the cytoplasmic
contents of the cells to become exposed and more easily
ionised. We therefore decided to test whether a freeze/thaw
cycle improved MALDI TOF MS analysis of mammalian cell
lines and whether freezing before or after a wash with PBS
affected sensitivity and spectral quality compared with direct
analysis (Fig. 1D).
Both methods of freeze/thawing permeated the cell mem-
brane of about 50–80% of the cells (Fig. 1E). This led to a sig-
nificant increase in the number of peaks identified compared
to “intact” cell samples (Fig. 1F). As well as this, software ana-
lysis did not result in a significant difference between cells
frozen before or after further treatment and manual inspection
of spectra resulted in the same conclusion (Fig. S2†). We con-
clude that a freeze/thaw cycle is critical to improve MALDI TOF
MS quality of mammalian cells as it increases the number of
features identified. However, the order in which this step is
performed does not affect the final readout.
Suitability of mammalian cell fixing techniques for whole cell
MALDI TOF-MS
Next, we took inspiration from cell and tissue fixing tech-
niques and examined how different fixing techniques influ-
Fig. 1 Optimising cell numbers for whole cell MALDI TOF MS. (A) Light microscopy images of four human cell lines U2OS, MCF7, THP1 and
HEK293. (B) 2D plot of normalised mass spectrum intensity at different cell numbers on the target for each of the four cell lines. Plots have maxima
indicating optimal cell numbers. (C) Plotting optimal cell numbers derived from (B) against their respective measured cell diameter shows a high cor-
relation. Plots in (B) derived from 6 technical replicates. Error bars represent standard deviation. (D) Schematic showing the workflow. (E) Trypan
blue staining of the four cell lines shows that the freeze/thaw cycle significantly increases the percentage of trypan blue positive cells and therefore
cell membrane permeability. (F) Number of peaks identified across six technical replicates for each of the experimental workflows shown in (D). Data
show that the number of features identified is significantly increased upon inclusion of a freeze/thaw cycle. Error bars represent standard deviation
of six replicates. *** and **** represent p < 0.001 and p < 0.0001, respectively, Student’s t-test.
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ence the preparation of mammalian cells for MALDI TOF MS
analysis. We hypothesised that the use of these techniques
would enable preservation of a specific cellular phenotype and
could be incorporated into a whole-cell MALDI TOF-MS com-
patible workflow. We chose to initially test formaldehyde and
alcohol fixing methods, methanol specifically, as they have
been used previously in MALDI imaging workflows.47 Initial
experiments revealed that samples treated with 4% PFA gener-
ated spectra that were 5–10× less intense than other methods,
(Fig. S3–6†); therefore we chose to continue by studying metha-
nol fixation versus the previously reported PBS washes. We sys-
tematically evaluated how both these methods performed with
respect to the number of identified peaks, and quality of the
acquired spectra, as well as technical reproducibility when ana-
lysed by MALDI TOF MS.
Both methanol and PBS washing steps distinguished each
of the four cell lines by both manual spectra interrogation and
PCA (Fig. 2A–F) and, each extraction method was able to gene-
rate a unique set of peaks for each of the four cell lines, thus
allowing classification of the different populations. As pheno-
type distinguishing peaks are often not the most intense fea-
tures and peaks identified with a lower S/N and intensity are
less likely to be quantified accurately, we therefore looked at
how the relative intensity of peaks was distributed for the top
10 most intense peaks for each cell line (Fig. 2G & H). This is
important for high-throughput analysis, and both PBS and
methanol treatment showed a generally even intensity distri-
bution. Finally, and arguably most importantly, we tested at
how reproducible peaks were identified over six technical repli-
cates (Fig. 2I & J, S2–5†). Methanol was the most consistent,
with the majority of all peaks being identified in all six
spectra, whereas PBS and water (pH 7) were slightly more vari-
able. Taken together, our data suggest that methanol fixation
is comparable if not superior to PBS washing for whole cell
analysis and may be ideal for classification of subtle
phenotypes.
Choosing a suitable matrix for mammalian cell MALDI TOF MS
Next, we tested which type of matrix allows for the best MALDI
TOF MS analysis of mammalian cells. The three matrices
mostly used in MALDI TOF MS of proteins and peptides are
SA, CHCA and DHB, which are often categorised for the ana-
lysis of proteins, peptides, and glycans, lipids and peptides,
respectively. However, when analysing whole mammalian cells
by MALDI TOF MS the origin of the biomolecules being
ionised is often unknown, and we therefore hypothesised that
the choice of matrix will have a significant influence on the
resulting mass spectrum.
As expected, when each cell line sample was prepared with
either saturated SA, CHCA or DHB, significantly different mass
profiles of the same cell line were observed (Fig. S7†). Using
the DHB matrix resulted in more variable spectra over techni-
cal replicates, with the PCA analysis using ClinPro Tools soft-
ware showing wider distances and grouping only three of the
six technical replicate spectra for MCF7 cells (Fig. S8A†).
Moreover, we could classify unique peaks to each of the
matrices (Fig. S8B†), which indicates that different bio-
Fig. 2 Methanol fixation and PBS washing are suitable for identifying reproducible features in whole cell MALDI TOF MS. (A and B) Number of ident-
ified unique features for any of the four cells after methanol fixation (A) and PBS washes (B). (C and D) PCA plots showing how multivariate analysis
can distinguish each of the four cell lines after methanol fixation (C) and PBS washes (D). (E and F) Number of peaks identified for each cell line over
six technical replicates. (G and H) Relative intensity distribution of the top 10 peaks identified over six technical replicates for each cell line. (I and J)
Pie charts displaying the % of peaks identified within each of the six replicates per cell line.
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molecules are being ionised and mammalian cell profiles are
matrix-dependent.
We then chose to look at how each matrix performs with
respect to concentration and increasing laser power. In all four
cell lines, CHCA performed significantly better with respect to
both parameters. Although each matrix performed optimally at
a saturated concentration, CHCA was able to yield much more
informative spectra and with more peaks identified at a third
of the concentration of DHB and SA. Following this, we
observed that the CHCA matrix was also able to ionise cellular
biomolecules at a much lower laser power than DHB and SA.
We were able to fit non-linear curves to these data, thereby
identifying the optimal minimal laser power and approximate
saturation points of each matrix (Fig. 3, Table 1). As CHCA is
known for ionising peptides and small proteins, these data
indicate that the biomolecules are either peptidic or small
molecular weight proteins.
We chose to take these data further to understand the
dynamics of matrix behaviour in a mock screen and evaluate
their performance across a 1536 target. We chose to use
methanol treated THP-1 cells that were then mixed with each
matrix using a Mosquito HTS and spotted in 200 nL aliquots.
Each target was then analysed at the approximate saturation
points described in Table 1: 60%, 80% and 90% for CHCA, SA
and DHB, respectively. When compared with a laser power of
60%, this corresponded to a laser energy fold change of 1.74×
and 2.30× for 80% (DHB) and 90% (SA), respectively. From
manual inspection as well as a positive MALDI response we
determined a spotting accuracy of >96% for each target
(Fig. 4A). This infers that methanol-fixed whole-cell samples
are compatible with current liquid handling technologies, as
well as MALDI TOF-MS.
We were also able to show that for CHCA and SA, the top five
most intense features were identified in >98% of spots, showing
robustness for high-throughput screening, whereas for samples
spotted with DHB peak identification is much more variable
(Fig. 4B). This is somewhat expected as DHB crystallises into
long, needle-like structures that produce a heterogeneous
surface. This combined with an inherently heterogeneous
sample such as fixed cells may account for this variability.
Fig. 3 Evaluating matrix performance when analysing whole cell samples by MALDI TOF MS. (A) Dependence of matrix concentration from
2.5–30 mg mL−1 (saturated) on the number of peaks identified for each of the four human cell lines and three matrices. (B) Laser power dependence
of each of the three matrices for each of the four cell lines. Non-linear regressions were fitted with a Sigmoidal, 4PL curve with good fits of
R2 >0.85–0.99. All error bars are given as standard deviations over six technical replicates.
Table 1 Laser power parameters determined from non-linear regression curves shown in Fig. 4B
Laser power parameters U2OS MCF7 THP1 HEK293
Matrix CHCA DHB SA CHCA DHB SA CHCA DHB SA CHCA DHB SA
Optimal laser power (%) 38 83 70 32 79 73 35 71 76 31 73 78
Saturation point (%) 60 ∼90 90 60 ∼90 80 50 ∼90 80 60 ∼90 90
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Overall spectral intensity based on the top five peaks as well as
the signal to noise ratio also varied significantly between the
matrix conditions. Samples spotted with CHCA exhibited much
greater spectral intensity compared to SA, and an almost 10-fold
increase when compared with DHB (Fig. 4C), as well as a signifi-
cantly better S/N ratio for these top 5 features (Fig. 4D).
Interestingly, we observed different lens contamination patterns
for each of the three matrices after accumulation of 3072 indi-
vidual spectra with each matrix (Fig. S9†). Both DHB and SA
yielded significant deposition of the matrix onto the lens com-
pared with CHCA. From our data set this does not appear to
negatively impact whole cell ionisation; however we do suspect
that prolonged ionisation and exposure to samples co-crystal-
lised with either SA or DHB will impact studies that have a
greater number of samples such as those in high throughput
screens. From these data, we conclude that CHCA would be the
matrix choice for whole cell analysis at a small and large scale
due to its superiority across the parameters discussed above.
However, we do report that for masses greater than >10 000 Da,
peak resolution is significantly improved by using SA (Fig. S10†)
and therefore may have a role to play in studies that identify sig-
nificant features in this mass range. Together, these results
show how phenotyping cells by MALDI TOF MS can be scaled
up to a high-throughput platform and still enable robust identi-
fication of cell specific features.
MALDI TOF MS profiling of pharmacologically controlled stem
cell differentiation
Finally, we wanted to apply our optimised workflow to pheno-
typically profile cells in a physiologically relevant system that
is employed in drug screening and toxicity testing and that has
been used as a drug discovery model.48 We used mESCs main-
Fig. 4 CHCA is the most suitable matrix for studies with a large sample number. (A) Mosquito spotting accuracy determined by positive signal
spectra and manual inspection for each of the matrices. Percentage of 1536 spots. (B) Percentage peak identification of the top 5 most intense
peaks over a 1536 target for each of the three matrices. (C) Frequency distribution of the top 5 most intense peak intensities of a 1536 target for
each of the three matrices. (D) Violin plots showing distribution of the signal-to-noise of the top 5 most intense peaks over a 1536 target for each of
the three matrices. Solid lines indicate median values and dotted lines the upper and lower quartiles.
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Fig. 5 Whole cell MALDI TOF MS distinguishes between naïve and differentiating mESCs (A) qPCR data showing changes in key mESC pluripotency
and differentiation genes. Error bars represent standard deviation of two technical replicates from three biological replicates. *** and **** represent
p < 0.001 and p < 0.0001, respectively, Student’s t-test. (B) PCA plot showing how the two cell populations can be distinguished by multivariate ana-
lysis over three biological and five technical replicates. (C) Z-Score heat map showing how each normalised peak intensity changes with respect to
2i and 2i release conditions over three biological and five technical replicates. (D) Selected examples of mass spectral regions that showed changes
between mESCs cultured under 2i and 2i release conditions where the base peak (4875 m/z) is of identical intensity, thus allowing relative intensity
comparison.
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tained in a naïve ground state pluripotency using the 2i kinase
inhibitor system (PD0325901 and CHIR99021), which inhibit
the kinases MEK1/2, upstream of ERK1/2, and GSK3, respect-
ively (Fig. S11†).40,49
Efficient exit from naïve ground state pluripotency towards
differentiation upon 2i release was confirmed by suppressed
mRNA expression of the naïve pluripotency factors Nanog and
Klf4, and induction of the lineage priming/differentiation
marker Fgf5 (Fig. 5A). As expected, the pluripotency factor
Pou5f1/Oct4, which is expressed in both naïve and lineage
primed mESC states, is not significantly altered upon acute 2i
release (Fig. 5A). Using MALDI TOF MS, we could robustly
identify unique features for each population, as well as quan-
tify changes in common peaks. For all spectra, the base peak
was identified at m/z 4875, which made subsequent analysis
simpler, as the raw spectral intensity can vary significantly
from spot-to-spot (Fig. 5D & Fig. S12†). Utilising m/z 4875, as a
normalising control, we identified a number of peaks that
were unique to 2i and 2i release, such as m/z 5566, 2i and 2i
release conditions could be well differentiated as two popu-
lations by PCA (Fig. 5B) and we observed good grouping of bio-
logical replicates. A similar distribution was identified when
using a jackknife method (Fig. S14, Table S3†).50 To further
understand how relative intensity of specific peaks changed
across the three biological and five technical replicates, we
generated a Z-score averaged based heatmap of detected mass
features relative to intensity (Fig. 5C). For robustness, data
were first filtered to include features that were identified in
30% of all technical replicates. A complete heatmap of all fea-
tures is presented in Fig. S15.† This hierarchical clustering
approach allowed us to look at the unique and common fea-
tures combined across all independent biological and techni-
cal replicates. The three biological replicates clustered well
together and 2i and 2i release conditions were separated
efficiently and two discrete row clusters emerged – peaks that
were up-regulated and those that were down-regulated upon
release from PD0325901 and CHIR99021 inhibitors. This cluster-
ing was significant in the hierarchical dendogram (Fig. S16†)
showing classification of the two different cell populations.
Through this, we identified several peaks that changed signifi-
cantly between the conditions and these can now be used as fea-
tures of phenotypic screening of mESC differentiation (Table 2).
Our MS approach has significant advantages over the conven-
tional qPCR approach with respect to time, cost and automation
possibilities. Using MALDI TOF MS and liquid handling robots,
samples could be processed in a 384 well plate format and ana-
lysed within one hour, approximately three times faster than
using qPCR. Furthermore, only 1000 cells are required to pheno-
type their differentiation state, comparable with qPCR, but the
consumable cost per sample is significantly reduced.
Consumables for our MALDI TOF MS assay are about £0.05–0.10
per sample, requiring only basic plastic ware, low solvent volume,
CHCA matrix and stainless steel MALDI targets. These are signifi-
cantly cheaper per sample compared to qPCR plate kits that typi-
cally cost >£2–5 per sample. Finally, our MALDI TOF MS approach
has the capability to be automated to a high-throughput scale
using already established technologies such as the Mosquito HTS.
Conclusion
Due to its speed and its relative simplicity, MALDI TOF MS has
become increasingly popular for the application of bacterial
biotyping. However, a complementary methodical approach to
phenotypic screening of mammalian cells has not been well
characterised. Here we presented a systematic study that
explores initial sample handling, matrix choice and suitability
of fixing techniques with whole cell MALDI TOF-MS analysis.
We found that all three steps had a profound impact on the
resulting mass spectra and subsequent data analysis. We also
applied a unique way of analysing the efficacy of each method
by looking at not only spectral quality and observable changes
but also evaluating performance over technical replicate spots.
This enabled us to gain a deeper understanding of how each
step of the sample preparation impacts subsequent analysis
and consequently an insight as to how each method would
perform with higher throughput analyses. Our optimised
method was validated by our observation of distinct MALDI
TOF MS profiles for naïve ground state mESCs compared to
differentiating mESCs in a pharmacologically controlled system.
Using hierarchical clustering, we could visualise and identify a
subset of peaks that are unique to each condition. We therefore
present here a novel sample preparation method that enables
robust, reproducible and rapid profiling of mammalian cells
and is suitable for expansion to a high-throughput platform.
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Table 2 Significant features identified in both 2i and 2i release spectra
that exhibit a greater than 2 fold change
m/z
Relative fold increase
2i 2i release
2437 x 2.03
5438 x 2.70
7148 x 2.08
7412 x 8.82
3097 4.57 x
4628 2.34 x
6197 3.18 x
11 174 2.86 x
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